The National Institute for
Clinical Excellence (NICE) has issued guidance
on the treatment and care of patients with
high blood pressure (hypertension) within the
NHS in England and Wales.
Hypertension: management of hypertension
in adults in primary care makes five
key recommendations:
1) Measuring blood pressure
Patients with single raised blood pressure readings of more than 140/90mmHg
should be asked to return for a minimum of two further blood pressure readings.
2) Assessing cardiovascular risk
Cardiovascular risk assessment should be conducted in hypertension patients
to help identify diabetes, evidence of hypertensive damage to the heart
and kidneys and secondary causes of hypertension such as kidney disease.
3) Lifestyle interventions
Lifestyle advice (eg, smoking cessation, diet, alcohol and caffeine consumption,
exercise) should be offered initially and then periodically to patients
undergoing assessment or treatment for hypertension.
4) Pharmacological interventions
Drug therapy should be offered to patients with persistent high blood pressure
(160/100 mmHg or more) and patients at raised cardiovascular risk (eg,
those with chronic heart disease, cardiovascular disease).
Recommendations are made for the use of
thiazide-type diuretics, beta-blockers, ACE-inhibitors
and dihydropyridine calcium-channel blockers.
5) Continuing treatment
An annual care review should be provided to monitor blood pressure, provide
support and discuss lifestyle, symptoms and medication. Patients without
cardiovascular disease and with well-controlled blood pressure wishing
to reduce or stop using drugs may be offered a trial reduction or withdrawal.
Forty per cent of British adults are believed
to live with hypertension. However, of that
figure it is estimated that a third are unaware
of their condition because there are no obvious
symptoms. NICE say this means it is often inadequately
treated, while those that do suffer from it
do not get the best treatment.
The need to address the problem is vital as
high blood pressure is also a major contributor
to cardiovascular diseases (eg, strokes and
heart attacks), which account for four million
NHS bed days and 30 per cent of all deaths
annually.
It is predicted that the new guidelines’ recommendations
to prescribe more could see a rise in drug
costs. Anti-hypertensive drugs cost the NHS £840m
in 2001 — almost 15 per cent of the primary
care drugs budget.
Chief
executive of NICE, Andrew Dillon said:
‘The aim of this guideline is to decrease
morbidity and mortality resulting from cardiovascular
diseases such as stroke, chronic renal failure
and coronary heart disease for which hypertension
is a significant risk factor. Hypertension
can be treated, in most cases, successfully.
The fact that a significant proportion of people
with this condition remain undiagnosed, coupled
with evidence that suggests a high incidence
of sub-optimal treatment — and therefore
poor rates of blood pressure control — for
those who are diagnosed, make this guideline
particularly significant.’
The Association of the British Pharmaceutical
Industry (ABPI) welcomed the guidance, in particular
the emphasis it places on the use of hypertension
drugs. Dr Richard Barker, director general,
said that it:
‘demonstrates once again that early
and tight management of a disease results in
better health for patients, reduces the number
of hospital stays and frees up capacity for
the NHS. Medicines have a key role to play
in achieving these aims.’
The Newcastle guideline development and research
unit (NGDRU) contributed to the finished guidelines,
which NICE asks local health communities to
read and then review their existing clinical
guidelines, care pathways and protocols.
|